Netflix's Q2 results beat expectations, with ad revenue set to double in 2025 as its ad-supported tier gains traction.
Elevance Health lowers profit forecast as medical costs surge, highlighting industry-wide challenges in controlling costs for government-backed health programs.
FDA reverses ban, authorizes Juul vapes for adults, sparking debate over youth vaping concerns.
Netflix's Q2 results beat expectations, with ad revenue set to double in 2025 as its ad-supported tier gains traction.
Elevance Health lowers profit forecast as medical costs surge, highlighting industry-wide challenges in controlling costs for government-backed health programs.
FDA reverses ban, authorizes Juul vapes for adults, sparking debate over youth vaping concerns.